Century Therapeutics
IPSC
65 hedge funds and large institutions have $107M invested in Century Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 6 closing their positions.
3,758% more call options, than puts
Call options by funds: $463K | Put options by funds: $12K
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
20% more funds holding
Funds holding: 54 → 65 (+11)
0.4% less ownership
Funds ownership: 35.83% → 35.43% (-0.4%)
49% less capital invested
Capital invested by funds: $209M → $107M (-$102M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$7.35M |
| 2 |
Millennium Management
New York
|
+$1.52M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.24M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.17M |
| 5 |
Renaissance Technologies
New York
|
+$992K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.08M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.55M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.16M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$1.69M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.24M |
IPSC Hedge Fund Activity: Q4 2022 in Review
65 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2022, worth a combined $107M — down 49% from $209M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IPSC positions and 6 closed out — a net gain of 11 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $7.35M. The largest seller was Marshall Wace, cutting an estimated $6.08M.
- 65 institutional investors held Century Therapeutics (IPSC) as of Q4 2022, up from 54 in Q3 2022.
- Funds reported $107M of Century Therapeutics stock for Q4 2022, down 49% quarter-over-quarter.
- 17 funds opened new Century Therapeutics positions in Q4 2022 and 6 closed out, a net change of +11 holders.
- The largest Century Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $7.35M added.
- The largest Century Therapeutics seller in Q4 2022 was Marshall Wace, an estimated $6.08M sold.
Based on aggregated 13F filings for Q4 2022.